PL2360255T3 - Sposób izolacji rozpuszczalnych polipeptydów - Google Patents

Sposób izolacji rozpuszczalnych polipeptydów

Info

Publication number
PL2360255T3
PL2360255T3 PL10190155T PL10190155T PL2360255T3 PL 2360255 T3 PL2360255 T3 PL 2360255T3 PL 10190155 T PL10190155 T PL 10190155T PL 10190155 T PL10190155 T PL 10190155T PL 2360255 T3 PL2360255 T3 PL 2360255T3
Authority
PL
Poland
Prior art keywords
identified
polypeptides
phage
human
biophysical properties
Prior art date
Application number
PL10190155T
Other languages
English (en)
Inventor
Jamshid Tanha
Original Assignee
Nat Res Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Council Canada filed Critical Nat Res Council Canada
Publication of PL2360255T3 publication Critical patent/PL2360255T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
PL10190155T 2005-03-25 2006-03-24 Sposób izolacji rozpuszczalnych polipeptydów PL2360255T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66495405P 2005-03-25 2005-03-25
EP10190155.1A EP2360255B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP06721715A EP1869182B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides

Publications (1)

Publication Number Publication Date
PL2360255T3 true PL2360255T3 (pl) 2015-05-29

Family

ID=37023360

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10190155T PL2360255T3 (pl) 2005-03-25 2006-03-24 Sposób izolacji rozpuszczalnych polipeptydów

Country Status (10)

Country Link
US (5) US8293233B2 (pl)
EP (46) EP2336327A1 (pl)
JP (7) JP5171611B2 (pl)
AT (1) ATE531800T1 (pl)
AU (1) AU2006227536B9 (pl)
CA (8) CA2873906C (pl)
ES (8) ES2534305T3 (pl)
PL (1) PL2360255T3 (pl)
PT (1) PT2360255E (pl)
WO (1) WO2006099747A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277897A1 (en) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US8445000B2 (en) 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
EP2336327A1 (en) * 2005-03-25 2011-06-22 National Research Council of Canada Method for isolation of soluble polypeptides
MX2009013328A (es) 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
EP2238165B1 (en) * 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-hiv domain antibodies and method of making and using same
WO2010060216A1 (en) * 2008-11-26 2010-06-03 National Research Council Of Canada Nanoaggregate embedded beads conjugated to single domain antibodies
CA2815888C (en) * 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CA2825552A1 (en) 2011-01-28 2012-08-02 National Research Council Of Canada Engineering of immunoglobulin domains
US20140161796A1 (en) * 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
EP3683312B1 (en) * 2013-04-23 2022-09-07 Elasmogen Limited Synthetic library of specific binding molecules
ES2924282T3 (es) 2014-12-19 2022-10-05 Medimmune Ltd Moléculas de transporte a través de la barrera hematoencefálica y usos de las mismas
RU2689689C2 (ru) 2015-01-23 2019-05-28 Хеликс Байофарма Корпорейшн Конъюгаты антитело-уреаза для терапевтических целей
CR20180234A (es) 2015-11-03 2018-09-11 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
IL314393A (en) * 2018-03-06 2024-09-01 Precigen Inc Human papillomavirus vaccines and their uses
WO2019173463A1 (en) 2018-03-06 2019-09-12 Intrexon Corporation Hepatitis b vaccines and uses of the same
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
WO2021127547A2 (en) 2019-12-19 2021-06-24 Quidel Corporation Monoclonal antibody fusions
AR124914A1 (es) * 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0542810A1 (en) * 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5965408A (en) * 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
PT1171468E (pt) * 1999-04-09 2008-10-08 Univ Zuerich Processo para a estabilização de imunoglobulinas quiméricas ou fragmentos de imunoglobulinas quiméricas e um fragmento de scfv anti-gep-2 estabilizado
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
DK1242457T3 (da) * 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
US6855810B2 (en) * 2000-03-27 2005-02-15 The Regents Of The University Of California Ligands directed to the non-secretory component, non-stalk region of plgR and methods of use thereof
EP1383793B1 (en) * 2000-03-29 2011-10-19 DGI BioTechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
ATE365749T1 (de) * 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
JP3375941B2 (ja) * 2000-11-24 2003-02-10 科学技術振興事業団 高効率抗体スクリーニング法
ES2376454T3 (es) * 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
WO2002059340A1 (en) 2001-01-26 2002-08-01 The Scripps Research Institute Immunopolypeptides to hepatitis c virus
DE10123041A1 (de) 2001-05-11 2002-11-28 Tobias Heintges Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus
WO2003014960A2 (en) * 2001-08-03 2003-02-20 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
JP4190005B2 (ja) 2001-08-22 2008-12-03 株式会社抗体研究所 結合性分子の選択方法
GB0124317D0 (en) * 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
WO2003059937A2 (en) 2002-01-14 2003-07-24 Washington University Synthetic ion channels
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
DK1506236T3 (da) * 2002-05-22 2013-03-04 Esbatech A Novartis Co Llc Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf
AU2003240822A1 (en) 2002-05-30 2003-12-19 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
WO2003104425A2 (en) * 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
CA2491471A1 (en) 2002-07-03 2004-01-15 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
AU2003282247A1 (en) 2002-11-15 2004-06-15 Medical Research Council Anti-activated ras antibodies
ES2340280T3 (es) 2003-03-14 2010-06-01 Wyeth Llc Anticuerpos dirigidos contra el receptor de il-21 humano y uso de los mismos.
EP1633316A4 (en) * 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
MXPA06010887A (es) 2004-03-23 2007-03-08 Amgen Inc Anticuerpos monoclonales especificos para ox4ol (cd 134l) humano.
RS51326B (sr) * 2004-08-05 2010-12-31 Genentech Inc. Humanizovani anti-cmet antagonisti
EP1789451A4 (en) 2004-08-12 2009-12-02 Dyax Corp TIE COMPLEX BINDING PROTEINS
EP2336327A1 (en) 2005-03-25 2011-06-22 National Research Council of Canada Method for isolation of soluble polypeptides
WO2010060216A1 (en) * 2008-11-26 2010-06-03 National Research Council Of Canada Nanoaggregate embedded beads conjugated to single domain antibodies
CA2825552A1 (en) * 2011-01-28 2012-08-02 National Research Council Of Canada Engineering of immunoglobulin domains
US20140161796A1 (en) * 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications

Also Published As

Publication number Publication date
JP6374851B2 (ja) 2018-08-15
EP2316948A1 (en) 2011-05-04
EP2368991B1 (en) 2016-02-17
ES2375826T3 (es) 2012-03-06
EP2330196A3 (en) 2012-04-18
EP2368997A2 (en) 2011-09-28
EP2336325A1 (en) 2011-06-22
EP2338999A2 (en) 2011-06-29
ES2558338T3 (es) 2016-02-03
EP2322622A2 (en) 2011-05-18
EP2338999A3 (en) 2012-05-23
EP2322624A2 (en) 2011-05-18
EP2360256B1 (en) 2014-12-31
EP2368991A3 (en) 2012-07-25
EP2336326A3 (en) 2012-02-15
JP2018110583A (ja) 2018-07-19
US20090220485A1 (en) 2009-09-03
EP2386638A3 (en) 2012-08-15
EP2368994A2 (en) 2011-09-28
EP2338997A1 (en) 2011-06-29
EP1869182B1 (en) 2011-11-02
ES2546788T3 (es) 2015-09-28
EP2333066A1 (en) 2011-06-15
EP2336326A2 (en) 2011-06-22
CA2868867A1 (en) 2006-09-28
EP2336323A3 (en) 2012-05-23
EP2360255A1 (en) 2011-08-24
EP2316946A1 (en) 2011-05-04
AU2006227536B9 (en) 2011-08-18
EP2386638A2 (en) 2011-11-16
JP5171611B2 (ja) 2013-03-27
CA2868774A1 (en) 2006-09-28
EP2333066B1 (en) 2015-02-18
AU2006227536A1 (en) 2006-09-28
EP2374886B1 (en) 2015-11-11
EP2336324A2 (en) 2011-06-22
CA2873939C (en) 2020-11-10
EP2330195A3 (en) 2012-05-23
US11091536B2 (en) 2021-08-17
ATE531800T1 (de) 2011-11-15
EP2333068A1 (en) 2011-06-15
EP2333067A1 (en) 2011-06-15
JP2014144010A (ja) 2014-08-14
US10150807B2 (en) 2018-12-11
AU2006227536B2 (en) 2011-08-11
ES2534305T3 (es) 2015-04-21
EP2368993A3 (en) 2012-06-13
EP2374886A2 (en) 2011-10-12
CA2873906A1 (en) 2006-09-28
ES2531537T3 (es) 2015-03-17
EP2330195A2 (en) 2011-06-08
EP2322621A2 (en) 2011-05-18
EP2339001A2 (en) 2011-06-29
EP2368996A3 (en) 2011-12-14
EP2360256A1 (en) 2011-08-24
JP2019187439A (ja) 2019-10-31
EP2377936A3 (en) 2012-06-13
CA2602028C (en) 2015-01-13
CA2873899C (en) 2020-11-10
EP2371960A3 (en) 2012-01-11
EP2368997A3 (en) 2012-02-22
EP2368994A3 (en) 2012-04-18
ES2550836T3 (es) 2015-11-12
CA2873939A1 (en) 2006-09-28
EP2316945A1 (en) 2011-05-04
EP2377936A2 (en) 2011-10-19
EP2368995A2 (en) 2011-09-28
EP2377935B1 (en) 2015-07-15
EP2339000A1 (en) 2011-06-29
JP6878508B2 (ja) 2021-05-26
EP2336328A1 (en) 2011-06-22
US11993643B2 (en) 2024-05-28
EP2322624A3 (en) 2012-03-14
EP2322624B1 (en) 2015-09-23
EP2338998A1 (en) 2011-06-29
EP2368993A2 (en) 2011-09-28
EP1869182A1 (en) 2007-12-26
US20220017603A1 (en) 2022-01-20
EP2336327A1 (en) 2011-06-22
EP2322621A3 (en) 2012-09-12
EP2377935A1 (en) 2011-10-19
EP2368990A1 (en) 2011-09-28
EP2316947A1 (en) 2011-05-04
EP2374886A3 (en) 2011-11-23
PT2360255E (pt) 2015-04-08
EP2368995A3 (en) 2012-01-18
EP2336323A2 (en) 2011-06-22
JP2008536490A (ja) 2008-09-11
EP2374887A3 (en) 2012-07-18
EP2351841A1 (en) 2011-08-03
CA2873906C (en) 2020-11-24
EP2374887A2 (en) 2011-10-12
EP2363485A1 (en) 2011-09-07
EP1869182A4 (en) 2008-08-13
JP5731956B2 (ja) 2015-06-10
ES2536995T3 (es) 2015-06-01
JP6628822B2 (ja) 2020-01-15
EP2345723A1 (en) 2011-07-20
EP2371960A2 (en) 2011-10-05
EP2330196A2 (en) 2011-06-08
EP2322623A3 (en) 2011-10-19
EP2368992A3 (en) 2012-03-14
EP2371961A1 (en) 2011-10-05
US20130142780A1 (en) 2013-06-06
CA2868865A1 (en) 2006-09-28
ES2565782T3 (es) 2016-04-06
JP2016073284A (ja) 2016-05-12
EP2360255B1 (en) 2015-01-28
US8293233B2 (en) 2012-10-23
WO2006099747A1 (en) 2006-09-28
EP2368991A2 (en) 2011-09-28
JP2016103998A (ja) 2016-06-09
JP2012070748A (ja) 2012-04-12
JP5901679B2 (ja) 2016-04-13
EP2368996A2 (en) 2011-09-28
EP2322622A3 (en) 2012-03-07
EP2322623A2 (en) 2011-05-18
US20160052995A1 (en) 2016-02-25
US20190092840A1 (en) 2019-03-28
CA2873899A1 (en) 2006-09-28
CA2868781A1 (en) 2006-09-28
CA2602028A1 (en) 2006-09-28
EP2368992A2 (en) 2011-09-28
EP2351842A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
EP1869182A4 (en) METHOD FOR ISOLATING SOLUBLE POLYPEPTIDES
WO2005111066A8 (en) Polypeptides from non-typeable haemophilus influenzae
WO2005040337A3 (en) METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
EA200702347A1 (ru) Способ получения глюкопиранозилзамещённых производных бензилбензола и промежуточных продуктов для их получения
WO2004043954A3 (en) Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same
WO2006017295A3 (en) Tetrapeptide analogs
WO2006116322A3 (en) Nicotinamide riboside kinase compositions and methods for using the same
IL178435A0 (en) Beta-carbolines useful for treating inflammatory disease
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
WO2007016029A3 (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
WO2006113907A3 (en) Escherichia coli o157:h7 proteins and uses thereof
NO20073156L (no) Stabilisering av radiofarmasoytiske forlopere
WO2005009361A3 (en) Method of treating hit patients with argatroban
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2009027056A3 (en) Antioxidant and paramagnetic heparin-nitroxide derivatives
EP1666880A4 (en) SCREENING METHOD
WO2004047615A3 (en) Hemiasterlin affinity probes and their uses
WO2005028666A3 (en) Determining kinase specificity
WO2007068913A3 (en) SRCR-B Domain Containing Proteins
WO2007108903A3 (en) Campylobacter vaccines and methods of use
WO2007020405A3 (en) Integrin i-domain binding peptides
WO2005010035A3 (en) Alternate reading frame polypeptides derived from hepatitis c and methods of their use
WO2006008266A3 (en) Factor xi-binding proteins
WO2004011648A3 (en) CYTOCHROME P450s